Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q4 2025 value amounting to $8.2 million.

  • Agios Pharmaceuticals' Change in Accured Expenses fell 3919.14% to $8.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.4 million, marking a year-over-year decrease of 13795.34%. This contributed to the annual value of -$1.4 million for FY2025, which is 13795.34% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Change in Accured Expenses of $8.2 million as of Q4 2025, which was down 3919.14% from $1.9 million recorded in Q3 2025.
  • In the past 5 years, Agios Pharmaceuticals' Change in Accured Expenses registered a high of $14.5 million during Q2 2025, and its lowest value of -$26.1 million during Q1 2025.
  • In the last 5 years, Agios Pharmaceuticals' Change in Accured Expenses had a median value of $2.3 million in 2021 and averaged $908900.0.
  • Per our database at Business Quant, Agios Pharmaceuticals' Change in Accured Expenses skyrocketed by 124416.67% in 2022 and then crashed by 36402.77% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Change in Accured Expenses (Quarter) stood at $2.7 million in 2021, then skyrocketed by 90.78% to $5.2 million in 2022, then skyrocketed by 143.13% to $12.7 million in 2023, then increased by 6.92% to $13.6 million in 2024, then crashed by 39.19% to $8.2 million in 2025.
  • Its Change in Accured Expenses stands at $8.2 million for Q4 2025, versus $1.9 million for Q3 2025 and $14.5 million for Q2 2025.